Non-Small Cell Lung Cancer Coverage from Every Angle
Editor:
David S. Ettinger, MD, FACP, FCCP
Advertisement
Advertisement

News

Use of Liquid Biopsy in Detecting Resistance After Targeted Therapy in Advanced NSCLC
AACR 2023: Learning More About How to Treat KRAS G12C–Mutated Lung Cancer
AACR 2023: Phase III AEGEAN Trial of Durvalumab-Based Therapy Meets Primary Endpoints in Resectable NSCLC
Phase III Neotorch Trial Shows Benefit of Toripalimab Plus Chemotherapy in Lung Cancer
AACR 2023: Surveillance of NSCLC Using Novel Circulating Tumor DNA Analysis
NCCN 2023: Next-Generation Tyrosine Kinase Inhibitors in Treatment of Metastatic Lung Cancer
Study Finds Link Between Guideline Adherence for Imaging and Survival in NSCLC
Atezolizumab Plus Bevacizumab: A Potential Option for Certain Patients With Nonsquamous Lung Cancer
Immune Checkpoint Inhibitors and Lung Cancer: Tumor Vasculature–Based Imaging Biomarker
FDA Approves Pembrolizumab as Adjuvant Therapy for NSCLC
Radiation and Immunotherapy Given Together May Be of Benefit for Some Patients With Lung Cancer
Adding a Novel Antibody to Anti–PD-1 Immunotherapy for Metastatic NSCLC
Neoadjuvant Atezolizumab: Focus of National Study in Resectable NSCLC
FDA Brief: Companion Diagnostic Approved for Tyrosine Kinase Inhibitor Treatment of NSCLC
Plasma T-Cell–Derived Circulating DNA Levels With Immunotherapy for Advanced-Stage NSCLC
FDA Brief: Accelerated Approval Granted for Adagrasib in KRAS G12C–Mutated Lung Cancer
I-ELCAP Trial Shows Long-Term Survival Benefits of Lung Cancer Screening
Can the Lung-MAP Composite Signature Predict Outcomes With Immunotherapy in NSCLC?
Can CD8-Positive, FoxP3-Positive Cells Predict Immunotherapy Response in NSCLC?
SITC 2022: Immunity Hubs and Response to Immunotherapy in NSCLC
Copyright © 2023 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.